Wellesley Pharmaceuticals
Newtown · Founded 2011
About Wellesley Pharmaceuticals
Wellesley Pharmaceuticals ensures that the ability of Nocturol to reduce and sometimes eliminate nocturia symptoms can be disseminated. Wellesley Pharmaceuticals is in the development of an innovative, patented drug for treating Nocturia (frequent urination at night). Currently, there are no drugs on the market focused on nocturia and Wellesley plans to be first to market in the space. They believe that their proprietary drug, Paxerol, positions them to be the industry leader, addressing a massive unmet clinical need. Paxerol offers a significant advancement in terms of mechanism of action relative to existing indirect treatments of nocturia and should allow them to provide relief to hundreds of millions of people.
Company Facts
- Founded: 2011
- Legal name: Wellesley Pharmaceuticals, LLC
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $7.9M
- Funding stage: Late Stage Venture
- Last round: Series C (Jan 2016)
- Website: wellesleypharma.com
- Phone: 1(215) 493-0168
Social Profiles
Canonical: https://fsome.com/organization/wellesley-pharmaceuticals-8406354 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.